2018 Debates and Didactics in Hematology and Oncology

Meeting Overview

The 2018 Debates and Didactics in Hematology and Oncology conference will feature a comprehensive review of mechanisms of disease and treatments for patients with cancer or blood disorders. Expert faculty from Winship Cancer Institute and thought leaders from across the nation will engage in interactive debates and didactic lectures on controversial topics and standards of care, offering you the opportunity to hear how science supports each point of view. Presentations and discussions will focus on current basic and clinical research, including the use of molecular targeted therapy, immunotherapies, and other novel therapeutic approaches.

Optional Agenda Sessions

Back by popular demand - Improving Your Presentation Skills: Going From Good to Great

Preparing a great presentation for a conference or seminar involves more than creating a slide deck. Join Judy Fortin, Senior Director of Communications for Winship Cancer Institute, for a session on Improving Your Presentation Skills. Participants will learn strategies and tactics for leaving your audience with the right information and the right impression.

Target Audience

This educational activity is intended for hematologists, oncologists, and other allied healthcare professionals interested in the management of hematology and oncology.

Learning Objectives

After successful completion of this educational activity, participants should be able to:


  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer

Fee Information

Registration Fees Before May 1 On or After May 1
Physician/PharmD/PhD $550 $650
Mid-level provider/Nurse $300 $375
Fellows, Residents, Students $25 $40
Pharmaceutical industry representative (non-exhibitor) $1000 $1200


For additional information contact Jaye Harden, or 678.892.1353.


Course Directors

  • Sagar Lonial, MD
    Professor and Chair, Department of Hematology and Medical Oncology
    Emory University School of Medicine
    Chief Medical Officer
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

  • Suresh S. Ramalingam, MD
    Professor, Department of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Director, Lung Cancer Program
    Assistant Dean for Cancer Research
    Co-Leader, Discovery & Developmental Therapeutics Program
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

Guest Faculty

  • Kenneth Anderson, MD
    Dana-Farber Cancer Institute
    Boston, Massachusetts
  • James O. Armitage, MD, FASCOD
    University of Nebraska Medical Center
    Omaha, Nebraska
  • Michael Atkins, MD
    Georgetown Lombardi Comprehensive Cancer Center
    Washington, DC
  • Hagop M. Kantarjian, MD
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas
  • Susan O’Brien, MD
    UC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California
  • Katherine B. Peters, MD, PhD
    The Preston Robert Tisch Brain Tumor Center at Duke University
    Durham, North Carolina

Winship Cancer Institute and Emory University Faculty

  • Mehmet Akce, MD
  • Pamela Blair Allen, MD, MSc
  • Cletus A. Arciero, MD, FACS
  • Martha L. Arellano, MD
  • Jonathan J. Beitler, MD, MBA, FACR, FASTRO
  • Mehmet Asim Bilen, MD
  • Kristie A. Blum, MD
  • William G. Blum, MD
  • Bradley C. Carthon, MD, PhD
  • Jonathon B. Cohen, MD, MS
  • Lesley B. Conrad, MD
  • Walter J. Curran, Jr, MD
  • Madhav V. Dhodapkar, MBBS
  • Bassel El-Rayes, MD
  • Christopher R. Flowers, MD, MS
  • Keerthi Gogineni, MD, MSHP
  • R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
  • Leonard T. Heffner, Jr, MD
  • Craig C. Hofmeister, MD, MPH
  • Jonathan L. Kaufman, MD
  • Christine L. Kempton, MD, MSc
  • Fadlo R. Khuri, MD, FACP
  • Rebecca B. Klisovic, MD
  • Vamsi K. Kota, MD
  • Ragini Kudchadkar, MD
  • Amelia A. Langston, MD
  • Mary Jo Lechowicz, MD
  • Michael C. Lowe, MD, MA
  • Shishir K. Maithel, MD
  • Viraj Master, MD, PhD, FACS
  • Morgan L. McLemore, MD
  • Jane L. Meisel, MD
  • Ajay K. Nooka, MD, MPH, FACP
  • Taofeek Owonikoko, MD, PhD
  • Elisavet Paplomata, MD
  • Mihir R. Patel, MD
  • Nabil F. Saba, MD, FACP
  • Walid L. Shaib, MD
  • Charles A. Staley, MD
  • Conor E. Steuer, MD
  • Mylin A. Torres, MD
  • Christina Wu, MD
  • Melinda L. Yushak, MD, MPH

SCHEDULE OVERVIEW

Wednesday, July 25, 2018

  • 5.00 PM – 6.30 PM Attendee & Exhibitor Check-In/Exhibit Set Up

Thursday, July 26 – Saturday, July 28, 2018

  • 7.30 AM – 3.00 PM Scientific Sessions (Breakfast & Lunch Included)

Sunday, July 29, 2018

  • 7.30 AM – 11.00 AM Scientific Sessions (Breakfast Included)


SOCIAL EVENTS

Thursday, July 26, 2018

  • 6.00 PM – 8.00 PM Family Dinner: Seafood Buffet

Saturday, July 28, 2018

  • 5.00 PM – 6.30 PM Closing reception


SCIENTIFIC SESSION AGENDA

Thursday, July 26

Lung Cancer/Head and Neck Cancer/Lymphoma/Leukemia

  • 7.30 AM General principles of immune therapy
    Madhav V. Dhodapkar, MBBS
  • 7.55 AM Stage 3 non-small cell lung cancer (NSCLC): Combined modality therapy and immunotherapy
    Walter J. Curran, Jr, MD, FACR
  • 8.20 AM Debate 1—What is the best predictive biomarker for immunotherapy in NSCLC?
    PD-L1 expression: Conor E. Steuer, MD
    Tumor mutation burden: Taofeek Owonikoko, MD, PhD
  • 8.45 AM Targeted therapy for NSCLC: EGFR and ALK
    Fadlo R. Khuri, MD, FACP
  • 9.10 AM Treatable molecular targets in NSCLC: BRAF, ROS1, NTRK, and MET
    Conor E. Steuer, MD
  • 9.35 AM Present status of immunotherapy for NSCLC
    Suresh S. Ramalingam, MD
  • 10.00 AM Break
  • 10.20 AM Debate 2— T4 larynx cancer can be treated with laryngeal conservation
    Yes: Jonathan J. Beitler, MD, MBA, FACR, FASTRO
    No: Mihir R. Patel, MD
  • 10.45 AM Dose-deintensification in HPV-positive squamous cell carcinoma of the head and neck (SCCHN)
    Nabil F. Saba, MD, FACP
  • 11.10 AM What is relevant for front-line treatment of indolent non-Hodgkin lymphoma (iNHL)?
    James O. Armitage, MD, FASCO
  • 11.35 AM What is the best approach for iNHL patients with early progression of disease?
    Jonathon B. Cohen, MD, MS
  • 12.00 PM Lunch
  • 12.25 PM Debate 3—What is the best front-line strategy for patients with Hodgkin lymphoma?
    ABVD: Christopher R. Flowers, MD
    AVD + Brentuximab: Kristie A. Blum, MD
    Pet Directed Therapy: Pamela Blair Allen, MD, MSc
  • 1.00 PM Comprehensive multidisciplinary care plans for cutaneous T-cell lymphoma
    Mary Jo Lechowicz, MD
  • 1.25 PM The role for targeted therapy in relapsed acute lymphoblastic leukemia
    Leonard T. Heffner, Jr, MD
  • 1.50 PM Acute myeloid leukemia (AML) moving beyond 7+3 with BEAT AML
    William G. Blum, MD
  • 2.15 PM Maintenance of certification (MOC)
  • 2.40 PM Adjourn

Friday, July 27

Gastrointestinal Cancers/Multiple Myeloma/ Leukemia/Other Hematologic Topics

  • 7.30 AM Debate 1—Stage IV microsatellite instability (MSI)-high colon cancer: Is there a role for
    chemotherapy
    Chemotherapy: Christina Wu, MD
    Immune therapy: Bassel El-Rayes, MD
  • 7.55 AM Neuroendocrine tumors: New data, new options
    Bassel El-Rayes, MD
  • 8.20 AM Salvage therapy for advanced pancreatic cancer
    Christina Wu, MD
  • 8.45 AM Hepatocellular cancer: Immune therapies and novel biologic agents
    Walid L. Shaib, MD
  • 9.10 AM Debate 2—Neoadjuvant therapy in resectable colorectal cancer liver metastasis is standard
    of care
    Yes: Mehmet Akce, MD
    No: Shishir K. Maithel, MD, FACS
  • 9.35 AM Prophylaxis and treatment of venous thromboembolism (VTE) in cancer
    Christine L. Kempton, MD, MSc
  • 10.00 AM Break
  • 10.20 AM New targets and treatments for relapsed multiple myeloma
    Kenneth Anderson, MD
  • 10.45 AM Debate 3—Minimal residual disease testing in multiple myeloma can be used to modify treatment
    Yes: Ajay Nooka, MD, MPH, FACP
    No: Jonathan L. Kaufman, MD
  • 11.10 AM Induction therapy and transplant for multiple myeloma
    Craig C. Hofmeister, MD, MPH
  • 11.35 AM Age and risk in treating myelodysplastic syndromes
    Martha L. Arellano, MD
  • 12.00 PM Molecular testing in myeloproliferative neoplasms: A primer
    Rebecca B. Klisovic, MD
  • 12.25 PM Lunch
  • 12.55 PM Debate 4—Targeted therapy vs immune therapy for acute myeloid leukemia (AML)
    Targeted therapy: Hagop M. Kantarjian, MD
    Immune therapy: William G. Blum, MD
  • 1.20 PM Allo transplant in CR1 for intermediate-risk AML
    Amelia A. Langston, MD
  • 1.45 PM Updates in treatment-free remission in chronic myeloid leukemia
    Vamsi K. Kota, MD
  • 2.10 PM Amyloidosis: Maximal application for best outcomes
    Jonathan L. Kaufman, MD
  • 2.35 PM LOC
  • 3.00 PM Adjourn

Saturday, July 28

Breast Cancer/Melanoma/Other Hematology Topics

  • 7.30 AM Debate 1—All patients with ductal carcinoma in situ (DCIS) need radiation after lumpectomy
    Yes: Mylin A. Torres, MD
    No: Cletus A. Arciero, MD, FACS
  • 7.55 AM Optimization of HER2 targeting in early-stage HER2+ breast cancer
    Elisavet Paplomata, MD
  • 8.20 AM PARP inhibition for the treatment of breast cancer
    Jane Lowe Meisel, MD
  • 8.45 AM Impact of cardiovascular risk modification/obesity on breast cancer outcomes
    Keerthi Gogineni, MD, MSHP
  • 9.10 AM Novel targets for cellular therapy in solid tumors
    Taofeek Owonikoko, MD, PhD
  • 9.35 AM Break
  • 9.55 AM Debate 2—Adjuvant therapy in melanoma: Immunotherapy vs BRAF/MEK inhibitors
    Targeted therapy: Ragini Kudchadkar, MD
    Immunotherapy: Melinda L. Yushak, MD, MPH
  • 10.20 AM Indications for complete lymph node dissection for early-stage melanoma
    Michael C. Lowe, MD, MA
  • 10.45 AM Systemic therapy for advanced-stage melanoma: What is the present standard of care?
    Ragini Kudchadkar, MD
  • 11.10 AM Surveillance of high risk melanoma: Routine imaging vs clinical follow-up
    Melinda L. Yushak, MD, MPH
  • 11.35 AM Tumor treating fields (TTF), antibody-drug conjugates (ADCs), and other advances in brain tumors
    Katherine B. Peters, MD, PhD
  • 12.00 PM Lunch
  • 12.30 PM Has targeted therapy replaced conventional chemotherapy in chronic lymphocytic leukemia?
    Susan M. O’Brien, MD
  • 12.55 PM Debate 3—Salvage therapy for relapsed diffuse large B-cell lymphoma
    Auto/Allo: Amelia A. Langston, MDCAR T: Jonathon B. Cohen, MD, MS
  • 1.20 PM Consultative hematology: Common presentations and workup
    Morgan L. McLemore, MD
  • 1.45 PM How phase I trials can improve your patient outcomes
    R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
  • 2.10 PM MOC
  • 2.30 PM Adjourn


Sunday, July 29

Genitourinary Cancers

  • 7.30 AM Role of hyperthermic intraperitoneal chemotherapy for ovarian cancer
    Charles A. Staley, MD
  • 7.55 AM Immunotherapy in ovarian cancer: Current strategies and future directions
    Lesley B. Conrad, MD
  • 8.20 AM Debate 1—Adjuvant tyrosine kinase inhibitor (TKI) should be given for high-risk renal cell
    carcinoma (RCC) after nephrectomy
    Yes: Viraj Master, MD, PhD, FACS
    No: Mehmet Asim Bilen, MD
  • 8.45 AM Immune therapy for bladder cancer
    Bradley C. Carthon, MD, PhD
  • 9.10 AM Prostate cancer therapy: What is the present state of the art?
    Mehmet Asim Bilen, MD
  • 9.35 AM Targeted therapy for RCC
    Michael B. Atkins, MD
  • 10.00 AM MOC
  • 10.25 AM Adjourn

Accomodations

We’re excited to let you know that hotel reservation requests are available online this year, during your registration process!


Accommodation Options


The Cloister Main Building and Wings
Cloister Gardenview Room $465 per night
Cloister Riverview Room $499 per night
Main Building 1 BR Suite – King only $499 per night
The Beach Club and Ocean Residences
Beach Club Room $499 per night
Beach Club 1 BR Suite $575 per night
The Lodge at Sea Island $425 per night
The Inn at Sea Island $225 per night

Taxes and Fees

Nightly rate is subject to a 2.25% infrastructure fee, and applicable taxes, currently 7% sales tax, 5% room tax, and a $5.00 state lodging tax.

Deposits

Your credit card will be charged by the hotel for 2 nights stay as a deposit. This amount will be refundable until June 1.

Reservation Confirmations and Changes

You will receive a confirmation email from the hotel once the transaction has been completed. Please allow 48 business hours for the reservations to be processed and the confirmation to be sent. Any changes or additional requests (with the exception of cancellations) should be made by returning to your registration to modify it online. If you have any question about this process, please email and cc .

Cancellations

All cancellation requests must be in writing, and sent to . Cancellations between June 1 (the hotel cut-off date) and July 15 will only be refunded if the room can be resold. No hotel room deposits will be refunded after July 15, 2018.

The Inn at Sea Island

Inn at Sea Island rate includes breakfast and access to private Sea Island facilities, with the exception of The Beach Club. Access to The Beach Club (with the exception of attending group events) is an additional $75 per adult/$50 per child, per night.

Parking

Valet parking is available to all overnight guests for a charge of $20 (discounted from $25 for the group) per night. Valet parking is required for guests staying in The Cloister Main Building. Self-parking is available to overnight guests staying at The Beach Club, Ocean Residences, and The Lodge, for a charge of $15.00 per night (discounted from $20 for the group). Parking at The Inn at Sea Island is complimentary.

Shuttles

Complimentary shuttles are available between The Cloister, The Lodge, and The Inn at Sea Island. The shuttles run from 7.00 AM to 11.00 PM, leaving on the hour and the half hour.

Services and Activities

A 10% discount on spa services and a 20% discount on golf is available to Debates and Didactics group guests. Bingo schedule (around the meeting dates): July 20th at 9.00 PM; July 24th at 5.30 PM and 9.00 PM; July 31st at 5.30 PM and 9.00 PM; August 2nd at 9.00 PM. Card sales begin 1 hour before start time. See the Sea Island website for dress code policy. Reservations for all services and activities can be made by visiting www.seaisland.com or calling 855.572.4975.

Exhibitor Package

The exhibit fee will allow one 6’ exhibit table and complimentary registration, including meals, for two company representatives for all four days of the conference. Additional company representatives may register separately. Exhibit set up will be on Wednesday evening and should remain in place for the duration of the meeting. Attendees will have the opportunity to visit the exhibits during breakfast each morning, at the morning breaks, and before and after the lunch session.


Standard Exhibit Fee: $5000
Premier Placement Exhibit Fee: $7500
Additional representatives may attend for $1000 a person ($1200 after May 1)

Registration

The name and email addresses of both representatives attending are required fields for the online registration process. Payment can be made by check or online by credit card.


PLEASE NOTE: If you choose to pay online via credit card, you will incur a 4% processing fee.


For payment by check, please make checks payable to prIME Oncology, LLC
Tax ID # 20-5392799 for the designated amount and send by overnight mail to:

prIME Oncology
5901 Peachtree Dunwoody Rd
Building C, Suite 250
Atlanta, GA 30328
Attention: Lisa Willey - DDHO


Download Forms

Please download the necessary forms, complete them, and return to Lisa Willey by email at Lisa.Willey@prIMEoncology.org.


Exhibit Request Letter
LOA – Premier Exhibit
LOA – Standard Exhibit
prIME LLC W-9

Cancellation

50% of the registration fee is refundable through May 25, 2018. Substitutions will be accepted up to one week prior to the meeting date with written notice.

Cancellation Fee Hotel Rooms

Cancellations between June 1 (the hotel cut-off date) and July 15 will only be refunded if the room can be resold. No hotel room fees will be refunded after July 15, 2018.


prIME Oncology does not accept responsibility for reimbursement of travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.


For additional information contact Jaye Harden, , or 678.892.1353.